Skip to content
Pharma Observatory a Scientist.com platform

Clinical trial

A Phase 4, Randomized, Double-Blind, Placebo-Controlled, Cross-over Trial to Evaluate the Effects of Ranolazine on Myocardial Perfusion Assessed by Serial Quantitative Exercise SPECT Imaging

NCT01221272 is registered in ClinicalTrials.gov with Gilead Sciences as lead sponsor.

NCT NCT01221272
Email me this page as a PDF

Search trials, sites, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.

Get the NCT01221272 report as a PDF

The PDF carries up to 50 rows of each section, where the page shows the first few, with the sources listed. Enter a work email and confirm it from the message we send, and the report follows by email.

Registry record

As filed in ClinicalTrials.gov.

Title
A Phase 4, Randomized, Double-Blind, Placebo-Controlled, Cross-over Trial to Evaluate the Effects of Ranolazine on Myocardial Perfusion Assessed by Serial Quantitative Exercise SPECT Imaging
Lead sponsor
Gilead Sciences
Phase
Phase 4
Overall status
Completed
Start date
September 30, 2010
Completion date
September 30, 2012
Enrollment
81 (actual)
Sites
43

Conditions

As the registry lists them; a condition with its own page is linked.

myocardial ischemia, myocardial perfusion imaging